Heart Failure Market Expected to Rise | Companies – Bristol-Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, BIAL, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca

Heart Failure Market
DelveInsight’s “Heart Failure Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Heart Failure, historical and forecasted epidemiology as well as the Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Heart Failure market growth is driven by factors like increase in the prevalence of Heart Failure, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Heart Failure market report also offers comprehensive insights into the Heart Failure market size, share, Heart Failure epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Heart Failure market size growth forward. 

Some of the key highlights from the Heart Failure Market Insights Report:

Several key pharmaceutical companies, including Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol-Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, BIAL, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, and others, are developing novel products to improve the Heart Failure treatment outlook. 
The total Heart Failure market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Heart Failure market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Heart Failure Market Landscape

Heart Failure Overview 

Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations. Heart failure is a pathological condition in which the heart is unable to pump enough blood to the rest of the body, because it is either unable to fill with a sufficient volume of blood or unable to generate sufficient force to pump out enough blood. Dysfunction of the pericardium, myocardium, endocardium, heart valves or great vessels alone or in combination is also associated with HF.

Heart failure can severely decrease the functional capacity of a patient and increase mortality risk. It is imperative to diagnose and effectively treat the disease to prevent recurrent hospitalizations, improve quality of life, and enhance patient outcomes. The treatment of heart failure requires a multifaceted approach involving patient education, optimal medical regimen to improve cardiac contractility, and prevention/limitation of exacerbations. The cardinal manifestations of HF are dyspnea and fatigue, which may limit exercise tolerance and fluid retention, which may lead to pulmonary and/or splanchnic congestion and/or peripheral edema. Heart failure, remains a stubborn problem and is now considered to be the greatest challenge in cardiovascular medicine and surgery.

Do you know the treatment paradigms for different countries? Download our Heart Failure Market Sample Report

Recent Breakthroughs in the Heart Failure Market

FDA Approves New Drug, Sotagliflozin, for Heart Failure: Sotagliflozin, a novel agent that inhibits sodium-glucose cotransporter (SGLT) 1 as well as SGLT2, received marketing approval from the US Food and Drug Administration (FDA) on May 26 for reducing the risk for cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in patients with heart failure, and also for preventing these same events in patients with type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular disease risk factors.
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure: INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes. INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to placebo in the SOLOIST-WHF study. 

Heart Failure Epidemiology Segmentation 

DelveInsight’s Heart Failure market report is prepared on the basis of an epidemiology model. It offers comprehensive insights to the Heart Failure historical patient pools and forecasted Heart Failure patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Heart Failure Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

Heart Failure Prevalence 
Age-Specific Heart Failure Prevalence 
Gender-Specific Heart Failure Prevalence 
Diagnosed and Treatable Cases of Heart Failure

Visit for more @ Heart Failure Epidemiological Insights

Heart Failure Treatment Market 

The Heart Failure market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Heart Failure market trends by analyzing the impact of current Heart Failure therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Heart Failure market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Heart Failure market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Heart Failure market in 7MM is expected to witness a major change in the study period 2019-2032.

Heart Failure Emerging Drugs

Tirzepatide: Eli Lilly and Company

Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in phase 3 development for chronic weight management and heart failure with preserved ejection fraction (HFpEF).

Finerenone (BAY94-8862): Bayer

Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block the harmful effects of the overactivated mineralocorticoid receptor (MR) system. MR overactivation is a major driver of heart and kidney damage. Current steroidal MRAs on the market have proven to be effective in reducing cardiovascular mortality in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, they are often underutilized due to the incidence of hyperkalemia, renal dysfunction, and anti-androgenic / progestogenic side effects.

The initiation of the Phase III FINEARTS-HF study (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure) builds upon the robust Phase II studies ARTS-HF and ARTS-DN which investigated the efficacy and safety of finerenone in patients with heart failure and chronic kidney disease, respectively. Data from the Phase II study program ARTS were presented at ESC Congress 2015 in London.

CardiAMP Cell Therapy: BioCardia

CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively screen for cell therapeutic potency in order to improve patient outcomes. CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy, which the company believes improves the probability of success of the treatment: a pre-procedural diagnostic for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial delivery systems and more successful for enhancing cell retention.

Firibastat: Quantum Genomics

Firibastat is the first drug candidate in a new class of therapeutic agents called BAPAIs (Brain Aminopeptidase an Inhibitors). Firibastat is a prodrug that releases EC33, a specific and selective inhibitor of Aminopeptidase A in the brain, thereby preventing the production of angiotensin III in the brain. After collecting excellent data on animal efficacy and human safety in the Phase IIa study, Quantum Genomics announced the design of its Phase IIb study in heart failure last June 2018 with Firibastat. Firibastat currently is in Phase II for the Heart Failure.

HU 6: Rivus Pharmaceuticals

HU6 is a controlled metabolic accelerator (CMA) that provides a novel, measured approach to activating proton leak and mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat throughout the body.

Heart Failure Key Companies

Zensun (Shanghai) Sci & Tech
Windtree Therapeutics
TreeFrog Therapeutics
Torrent Pharmaceuticals
Tenaya Therapeutics
Tasly Pharmaceuticals
Stealth BioTherapeutics
SQ Innovation
Shanghai Hongyitang Biopharmaceutical Technology
Sana Biotechnology
Salubris Biotherapeutics
Rivus Pharmaceuticals
Renova Therapeutics
Regeneron Pharmaceuticals
Quantum Genomics
Procella Therapeutics
Paradigm biopharmaceuticals
Palatin Technologies
Orizuru Therapeutics
Olatec Therapeutics
Novo Nordisk
Mesoblast Inc.
Merck & Co
Lexicon Pharmaceuticals
Janssen Research & Development
Ionis Pharmaceuticals
Intra-Cellular Therapies
Imbria Pharmaceuticals
Imara Inc
Hyloris Pharmaceuticals
Help Therapeutics
HAYA Therapeutics
GB Sciences
Fujifilm Corporation
Evotec SE
Eli Lilly and Company
Edgewise Therapeutics
Chong Kun Dang
Cardurion Pharmaceuticals
Cardior Pharmaceuticals
Cardiol Therapeutics
Bristol-Myers Squibb
Boryung Pharmaceutical
BlueRock Therapeutics
Berlin Cures
Asklepios Biopharmaceutical
Antlia Biosciences
Actelion Pharmaceuticals

For more information, visit Heart Failure Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Heart Failure Market Report:

11 Years Forecast
7MM Coverage 
Descriptive overview of Heart Failure, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Heart Failure epidemiology in the 7MM
Heart Failure marketed and emerging therapies 
Heart Failure companies
Heart Failure market drivers and barriers 

Key Questions Answered in the Heart Failure Market Report 2032:

What was the Heart Failure market share distribution in 2019, and how would it appear in 2032?
What is the total Heart Failure market size and the market size by therapy across the 7MM for the study period (2019-32)?
What are the important findings from 7MM, and which country will have the greatest Heart Failure market size from 2019-32?
During the study period (2019-2032), at what CAGR is the Heart Failure market projected to expand at 7MM?

Table of Contents:

1 Heart Failure Market Key Comprehensive Insights 

2 Heart Failure Market Report Introduction

3 Competitive Intelligence Analysis for Heart Failure

4 Heart Failure Market Analysis Overview at a Glance

5 Executive Summary of Heart Failure

6 Heart Failure Epidemiology and Market Methodology

7 Heart Failure Epidemiology and Patient Population

8 Heart Failure Patient Journey

9 Heart Failure Treatment Algorithm, Heart Failure Current Treatment, and Medical Practices

10 Key Endpoints in Heart Failure Clinical Trials

11 Heart Failure Marketed Therapies 

12 Heart Failure Emerging Therapies

13 Heart Failure: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Heart Failure

16 Heart Failure Market Key Opinion Leaders Reviews

18 Heart Failure Market Drivers

19 Heart Failure Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Heart Failure Epidemiology 2032

DelveInsight’s “Heart Failure – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Heart Failure epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Heart Failure Pipeline 2023

“Heart Failure Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Heart Failure market. A detailed picture of the Heart Failure pipeline landscape is provided, which includes the disease overview and Heart Failure treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: